Abstract
The fiield of angiogenesis research has undergone dramatic growth in recent years, as evidenced by the massive number of citations appearing in the medical literature (1). Until very recently, the focus of most work has been on defining the steps in the angiogenesis cascade, and the naturally occurring factors that both induce and inhibit the process. Over 20 years ago, Judah Folkman postulated that if tumor angiogenesis could be inhibited, then a potentially novel and effective treatment strategy could be developed for solid tumors (2). That hope is now coming to fruition as novel agents that inhibit tumor angiogenesis are entering clinical trials. As outlined in previous chapters, many of the compounds that are known to inhibit angiogenesis behave in a cytostatic fashion. Unlike classic cytotoxic chemotherapy agents, inhibitors oftumor angiogenesis may not cause tumor shrinkage but instead maintain a stable tumor size. The challenge facing clinical investigators and pharmaceutical companies developing these drugs is to carefully and thoughtfully design clinical trials that take into consideration the cytostatic behavior of angiogenesis inhibitors (AI) (3). Assessments of efficacy of AIs must avoid the trap of requiring tumor shrinkage
in order to continue clinical development. As a result, end points other than tumor regression must be incorporated into clinical trial design.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Gasparini, G. (1996) Angiogenesis research up to 1996. A commentary on the state of the art and suggestions for future studies. Eur. J. Cancer 32A, 2379–2385.
Folkman, J. (1971) Tumor angiogenesis. Therapeutic implications. N. Engl. J. Med. 285, 1182–1186.
Pluda, J. M. (1997) Tumor-associated angiogenesis: mechanisms, clinical implications and therapeutic strategies. Semin. Oncol. 24, 203–218.
Mani, S. and Ratain, M. J. (1997) New phase I trial methodology. Semin. Oncol. 24, 253–261.
Schwartsmann, G., Wanders, J., Koier, I. J., et al. (1991) EORTC New Drug Development Office coordinating and monitoring programme for phase I and II trials with new anticancer agents. Eur. J. Cancer 27, 1162–1168.
Markman, M. (1986) Ethical dilemma of phase I clinical trials. CA Cancer J. Clin. 36, 367–369.
Ratain, M. J., Mick, R., Schilsky, R. L., et al. (1993) Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J. Natl. Cancer Inst. 85, 1637–1643.
Greishaber, C. K. and Marsoni, S. (1986) Relation of preclinical toxicology to findings in early clinical trials. Cancer Treat. Rep. 70, 65–72.
Newell, D. R. (1994) Pharmacology based phase I trials in cancer chemotherapy. Hematol. Oncol. Clin. North Am. 8, 257–275.
National Cancer Institute (1988) Guidelines for Reporting of Adverse Drug Reactions. Division of Cancer Treatment, National Cancer Institute, Bethesda, MD.
O’Quigley, J., Pepe, M., Fisher, L. (1990) Continual reassessment methods of practical design for phase I clinical trials in cancer. Biometrics 46, 33–48.
Korn, E. L., Midthune, D., Chen, T. T., et al. (1994) Comparison of two phase I trial designs. Stat. Med. 13, 1799–1806.
Gordon, N. H. and Wilson, J. K. V. (1992) Using toxicity grades in the design and analysis of cancer phase I clinical trials. Stat. Med. 11, 2063–2075.
Mick, R. and Ratain, M. J. (1993) Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. J. Natl. Cancer Inst. 85, 217–223.
Graham, M. A. and Worman, P. (1992) Impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies. Ann. Oncol. 3, 339–347.
Bolognese, J. A. (1983) Monte Carlo comparison of three up and down designs for dose ranging. Controlled Clin. Trials 4, 187–196.
Kerr, D. J. (1994) Phase I clinical trials: adapting methodology to face new challenges. Ann. Oncol. 5(Suppl. 4), 67–76.
Miller, A. B., Hoogstraten, B., Staquet, M., et al. (1981) Reporting results of cancer treatment. Cancer 47, 207–214.
Howell, A., McIntosh, J., Jones, M., et al. (1988) Definition of the “no charge” category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur. J. Cancer. Clin. Oncol. 24, 1567–1572.
Jordan, V. C. and Gradishar, W. J. (1997) Molecular mechanisms and future uses of antiestrogens. Mol. Asp. Med. 18, 171–247.
Jonat, W., Howell, A., Blomquist, C., et al. (1996) A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer 32A, 404–412.
Polverini, P. J., Bouck, N. P., and Rastinejad, F. (1991) Assay and purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol. 198, 440–450.
Lingen, M. W., Polverini, P. J., and Bouck, N. P. (1996) Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab. Invest. 74, 476–483.
Talbot, D. C. and Brown, P. D. (1996) Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur. J. Cancer 32A, 2528–2533.
Basset, P., Bellocq, J. P., Wolt, C., et al. (1990) Novel metalloproteinase gene specifically expressed in stromal cell of breast carcinomas. Nature 348, 699–704.
Yoshimoto, M., Itoh, F., Yamamoto, H., et al. (1993) Expression of MMP-7 (Pump-1) mRNA in human colorectal cancers. Int. J. Cancer 54, 614–618.
Okada, Y., Naka, K., Kawamura, K., et al. (1995) Localization of matrix metalloproteinase 9 in osteoclasts: implications for bone resorption. Lab. Invest. 72, 311–322.
Gohji, K., Fujimoto, N., Fujii, A., et al. (1996) Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinase-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res. 56, 3196–3198.
Weidner, N. (1995) Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 147, 9–19.
Fox, S. B. (1997) Tumor angiogenesis and prognosis. Histopathology 30, 294–301.
Vermeulen, P. B., Gasparini, G., Fox, S. B., et al. (1996) Quantification of angiogenesis in solid tumors: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer 32A, 2474–2484.
Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. (1991) Tumor angiogenesis and metastasiscorrelation in invasive breast carcinoma. N. Engl. J. Med. 324, 1–8.
Gasparini, G. (1996) Clinical significance of the determination of angiogenesis in human breast cancer: update ofthe biological background and overview of the Vicenza studies. Eur. J. Cancer. 32A, 2485–2493.
Burrows, F. J., Derbyshire, E. J., Tazzari, L., et al. (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res. 1, 1623–1634.
DeFriend, D. J., Howell, A., Nicholson, R. I., et al. (1994) Investigation of a pure new antiestrogen (ICI 182, 780) in women with primary breast cancer. Cancer Res. 54, 408–414.
Fujimoto, K., Ichimori, Y., Yamaguchi, H., et al. (1995) Basic fiibroblast growth factor as a candidate tumor marker for renal cell carcinoma. Jpn. J. Cancer Res. 86, 182–186.
Nyugen, M., Watanabe, H., Budson, A. E., et al. (1994) Elevated levels of an angiogenic peptide, basic fiibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl. Cancer Inst. 86,356–361.
Yamamoto, Y., Toi, M., Kondo, S., et al. (1996) Concentrations of vascular endothelial growth factor in sera of normal control and cancer patients. Clin. Cancer Res. 2, 821–826.
Taniguchi, T., Toi, M., Inada, K., et al. (1995) Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin. Cancer Res. 1, 1031–1034.
Takahashi, Y., Tucker, S. L., Kitadai, Y., et al. (1997) Vessel counts and expression of vascular endothelial growth factors as prognostic factors in node-negative colon cancer. Arch. Surg. 132, 541–546.
Takano, S., Yoshii, Y., Kondo, S., et al. (1996) Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 56, 2185–2190.
Kondo, S., Asano, M., Matsuo, K., et al. (1994) Vascular endothelial growth factor/vascular permeability factor is detectable in sera of tumor-bearing mice and cancer patients. Biochem. Biophys. Acta. 1221, 211–214.
Moskal, T. L., Huang, S., Ellis, L. M., et al. (1995) Serum levels of transforming growth factor alpha in gastrointestinal cancer patients. Cancer Epidemiol. Biomarkers Prev. 4, 127–131.
Chekrabarty, S., Huang, S., Moskal, T. L., et al. (1994) Elevated serum levels of transforming growth factor-alpha in breast cancer patients. Cancer Lett. 79, 157–160.
Chopra, V., Dinh, T. V., and Hannigan, E. V. (1997) Serum levels of interleukins, growth factors and angiogenesis in patients with endometrial cancer. J. Cancer Res. Clin. Oncol. 123, 167–172.
Malfetano, J., Teng, N., Barter, J., et al. (1997) Marimastat in patients with advanced cancer of the ovary: a dose-finding study. Proc. Am. Soc. Clin. Oncol. 16, 373a.
Zaknoen, S., Wolff, R., Cox, J., et al. (1997) Marimastat in advanced progressive colorectal cancer: a dose-finding study. Proc. Am. Soc. Clin. Oncol. 16, 273a.
American Society of Clinical Oncology (1996) Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J. Clin. Oncol. 14, 2843–2877.
Smith, D. C. and Pienta, K. J. (1997) Use of prostate-specific antigen as a surrogate endpoint in the treatment of patients with hormone refractory prostate cancer. Urol. Clin. North Am. 24, 433–437.
Blanke, C. D. and Johnson, D. H. (1997) Treatment of small cell lung cancer. Semin. Thorac. Cardiovasc. Surg. 9, 101–110.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gradishar, W.J. (1999). Endpoints for Determination of Efficacy of Antiangiogenic Agents in Clinical Trials. In: Teicher, B.A. (eds) Antiangiogenic Agents in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-453-5_19
Download citation
DOI: https://doi.org/10.1007/978-1-59259-453-5_19
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-4518-4
Online ISBN: 978-1-59259-453-5
eBook Packages: Springer Book Archive